Safety of SP-420 in the Treatment of Transfusional Iron Overload
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with
transfusional iron overload and treats them with the investigational iron chelator, SP-420.
SP-420 may be better tolerated and safer than commercially available iron chelators. Iron
chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is
poor due to problems related to ease of administration, tolerability, and safety.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio